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Recurrent patterns of DNA copy number alterations
in tumors reflect metabolic selection pressures
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Abstract
Copy number alteration (CNA) profiling of human tumors has
revealed recurrent patterns of DNA amplifications and deletions
across diverse cancer types. These patterns are suggestive of
conserved selection pressures during tumor evolution but cannot
be fully explained by known oncogenes and tumor suppressor
genes. Using a pan-cancer analysis of CNA data from patient
tumors and experimental systems, here we show that principal
component analysis-defined CNA signatures are predictive of
glycolytic phenotypes, including 18F-fluorodeoxy-glucose (FDG)
avidity of patient tumors, and increased proliferation. The primary
CNA signature is enriched for p53 mutations and is associated with
glycolysis through coordinate amplification of glycolytic genes and
other cancer-linked metabolic enzymes. A pan-cancer and cross-
species comparison of CNAs highlighted 26 consistently altered
DNA regions, containing 11 enzymes in the glycolysis pathway in
addition to known cancer-driving genes. Furthermore, exogenous
expression of hexokinase and enolase enzymes in an experimental
immortalization system altered the subsequent copy number
status of the corresponding endogenous loci, supporting the
hypothesis that these metabolic genes act as drivers within the
conserved CNA amplification regions. Taken together, these results
demonstrate that metabolic stress acts as a selective pressure
underlying the recurrent CNAs observed in human tumors, and
further cast genomic instability as an enabling event in tumori-
genesis and metabolic evolution.
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glycolysis; metabolism
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Introduction
Cancer cells differ from normal cells in that they exhibit aberrant
proliferation, resist apoptosis, and invade other tissues (Hanahan &
Weinberg, 2011). Modern cancer classification relies on molecular
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characterization, including examination of genomic DNA mutations
and copy number alterations (CNAs; Stuart & Sellers, 2009).
Although individual oncogenes and tumor suppressor genes are
preferential targets of DNA amplifications and deletions, respec-
tively, the recurrent CNA patterns in tumors cannot be fully
explained by canonical cancer genes (Beroukhim et al, 2010; Muller
et al, 2012; Davoli et al, 2013). Thus, the unexplained recurrent
CNA patterns observed in human cancer subtypes are suggestive of
additional, not yet fully defined, selective pressures that are
conserved across patients and tumor types (Cahill et al, 1999;
Sheltzer, 2013; Cai et al, 2016). Reports that the cumulative pheno-
typic effects of many small gene dosage alterations across the
genome can impact the resulting tumor copy number landscape
(Solimini et al, 2012; Davoli et al, 2013) illustrate a need to consider
more subtle and combinatorial effects to explain the remaining
selective forces underlying recurrent CNA patterns observed in
human cancers.
One of the fundamental and consequential differences between
non-transformed and tumorigenic cells is the reprogramming of
cellular metabolism (Hanahan & Weinberg, 2011). The altered
metabolism of tumors is thought to benefit transformed cells in
several ways. Upregulation of glucose metabolism allows prolifer-
ating cells to meet their energy demand through synthesis of
adenosine triphosphate (ATP), while increased flux through
glycolysis branch pathways provides dividing cells with intermedi-
ates necessary for biosynthesis of nucleotides and fatty acids, as
well as reducing agents such as glutathione and NADPH
(DeBerardinis et al, 2008; Cairns et al, 2011). Moreover, in addi-
tion to glucose, cancer cells frequently upregulate consumption of
other metabolites for energy and biomass generation, including
glutamine, serine, and glycine (Jain et al, 2012; Maddocks et al,
2013). Notably, several individual metabolic enzymes have been
directly implicated in tumorigenesis (Kim et al, 2007; Dang et al,
2009; Locasale et al, 2011; Possemato et al, 2011; Patra et al,
2013; Li et al, 2014; Wang et al, 2014; Xie et al, 2014) and/or
immortalization (Kondoh et al, 2005; Kondoh, 2009; Kaplon et al,
2013), suggesting that altered metabolism is not a passive
bystander, but rather a driving force of oncogenesis (Yun et al,
2009; Zhang et al, 2012). Using an integrative analysis of CNA
data from human tumors, mouse models of cancer, cancer cell
lines, and a murine experimental immortalization system, here we
show that the loci of metabolic genes impact the recurrent CNA
changes observed in genomically unstable tumors. Our bioinfor-
matic and experimental results support a tumorigenesis model in
which copy number changes in metabolic genes contribute to an
enhanced glycolytic and proliferative state (see Fig EV1 for a
schematic of our overall approach).
Results
PCA-defined CNA signatures in human cancers
To develop an unbiased understanding of DNA copy number alter-
ations (CNAs) in cancer, we performed principal component analy-
sis (PCA) of gene-based CNA data derived from comparative
genomic hybridization (CGH) microarrays from 15 tumor types
available from The Cancer Genome Atlas (TCGA). This pan-cancer
PCA revealed a high degree of similarity in CNA profiles between
basal breast invasive carcinoma (BRCA basal), lung squamous cell
carcinoma (LUSC), ovarian serous cystadenocarcinoma (OV), and
serous uterine corpus endometrial carcinoma (UCEC serous) (Fig 1A
and Appendix Fig S1). In tumor type-specific PCA, analyzing the
four tissue-defined tumor sets of BRCA, LU (lung cancer consisting
of LUSC and LUAD [lung adenocarcinoma]), OV, and UCEC
revealed two strong PCA-based CNA signatures, termed signatures
A and B, in all four cases. Notably, signature A was highly consis-
tent across each tumor type, and reflected the pattern of pan-cancer
PC1 loadings (Figs 1B and C, and EV2A–C). In BRCA, signature A
tumors were enriched for the basal subtype, p53 point mutations,
high numbers of genomic breakpoints, and thus subchromosomal
alterations (Figs 1B and D, and EV2D; P < 0.001, P < 0.001,
P = 2 × 104, respectively). Signature B BRCA tumors, in contrast,
were enriched for luminal type tumors (P < 0.001) and exhibited
amplifications of the oncogenes MYC and MDM2 and deletion of the
tumor suppressor CDKN2A (Fig 1B). Amplification of MDM2 and
loss of CDKN2A were generally mutually exclusive in signature B
tumors (Fig EV2E), reflecting alternate mechanisms for disabling
the p53/ARF axis (Sherr & Weber, 2000). In the other tissues, signa-
ture A tumors were enriched for lung squamous cell carcinomas,
the proliferative subtype of ovarian cancer (The Cancer Genome
Atlas Research Network, 2011), and the serous subtype of uterine
cancer (Fig EV2A–D). Overall, signature A tumors demonstrated
enrichment of p53 mutations, more genomic breakpoints (BRCA,
LU, and UCEC), and a higher degree of copy number alterations
(LU, OV, and UCEC) than signature B tumors (Appendix Fig S2A
and B, P-values indicated in figure). In signature A tumors, the per
tumor average segment size is on the scale of 1 × 107 base pairs (ap-
proximately one-tenth of a chromosome, containing on the order of
100 genes). Overall, the segment sizes in signature A span from
focal to arm-length/whole chromosome scale. The per tumor aver-
age segment size for signature B BRCA, LU, and UCEC tumors is
statistically larger by 1.3-fold to sevenfold (Appendix Fig S2C–E;
P = 2 × 104 or less). Unlike signature A tumors, the signature B
CNA patterns were quite distinct between tumor types, although
some commonalities were observed including point mutations in
oncogenes such as KRAS (LU and UCEC) and amplification of
MYC (BRCA, LU, and OV). An alternative approach using
hierarchical clustering confirmed the existence of the shared pan-
cancer CNA signatures across multiple tumor types (signature A),
as well as distinct signature subtypes within each of the BRCA,
OV, UCEC, and LU tumor types (signature A vs. signature B)
(Fig EV3 and Appendix Fig S3, P-values of concordance between
PCA and clustering approaches indicated in figure). In summary,
PCA revealed the CNA signature A as a pattern shared across a
subset of tumors in multiple tissue types, as well as several
tumor type-specific cases of more distinct signature B patterns
(Appendix Fig S1D).
Because altered metabolism is a hallmark of human tumors, we
next tested whether the shared CNA signature A was enriched for
genes from metabolic pathways. Using CNA-based gene set enrich-
ment analysis over all metabolic pathways defined by KEGG
(Kanehisa et al, 2014), we found that the conserved profile of core
signature A tumors (i.e., OV, BRCA, UCEC, LU) (Fig 1C) was signifi-
cantly enriched for DNA amplifications of core glycolysis pathway
genes (Fig 1E and F, and Table EV1; P = 0.024). For example, BRCA
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3
signature A tumors exhibited DNA amplification of most genes from
the glycolytic pathway, as well as amplification of lactate dehydro-
genase B, deletion of pyruvate dehydrogenase subunits A and B,
and amplification of the glycolysis-regulating metabolic enzyme
TIGAR (human gene C12orf5; Fig 1G). Notably, this shared CNA
signature was defined by genome-wide patterns, rather than by
single gene loci, which were not consistently altered in all tumors
with a strong signature (Appendix Fig S2F). Interestingly, signature
A summary profiles from breast, ovarian, uterine, and lung tumors
all exhibited hexokinase 2 (HK2) amplification (Fig 1F and G),
whereas signature B profiles had primarily either HK3 (BRCA, LU,
OV) or HK1 (UCEC) amplification (Fig 1G and Appendix Fig S2G).
Thus, PCA identified a shared signature from breast, lung, ovarian,
and uterine carcinomas that was enriched for p53 mutations, higher
numbers of genomic breakpoints, and CNA of genes from the core
glycolysis pathway.
Elimination of passenger genes via cross-species
synteny mapping
While canonical oncogenes and tumor suppressor genes drive some
recurrent DNA copy number alterations, many recurrent CNA
regions cannot be fully explained by the presence of known cancer
genes (Beroukhim et al, 2010; Muller et al, 2012; Davoli et al,
2013). The conservation of CNA signature A across breast, lung,
ovarian, and uterine tumor subsets suggests the existence of one or
more selective pressures that are potentially shared by additional
tumor types. In that many of the human signature A conserved
regions identified in Fig 1C still span large, chromosome-scale
regions, we hypothesized that passenger genes could be diluting the
enrichment signal. We subsequently reasoned that a previously
reported approach of cross-species comparison of CNA data from
human tumors and non-human tumorigenesis models would elimi-
nate passenger genes via synteny mapping (Maser et al, 2007;
Zhang et al, 2013; Tang et al, 2014).
For the cross-species analysis, we first empirically determined
the full set of human signature A-like tumor tissue types that could
be included based on CNA similarity as defined by the pan-cancer
PC1 scores from Fig 1A. Namely, we sequentially added each
human tumor type in order of decreasing pan-cancer PC1 score and
tested whether inclusion improved the overall pathway enrichment.
In a parallel analysis, at each sequential step we also added the
corresponding tissue-matched mouse epithelial cancer model signa-
ture if it existed. Mouse CNA signatures obtained from the literature
and public repositories included signatures for genetically engi-
neered mouse models of mammary (breast) cancer (Brca) (Drost
et al, 2011; Herschkowitz et al, 2012), melanoma (Skcm)
(Viros et al, 2014), glioblastoma/high-grade astrocytoma (Gbm)
(Chow et al, 2011), and prostate cancer (Prad) (Ding et al, 2012;
Wanjala et al, 2015), as well as in vitro mouse epithelial cell models
of bladder (Blca), colorectal (Coad), and kidney (Kirc) cancer
(Padilla-Nash et al, 2013).
▸Figure 1. Principal component analysis (PCA) reveals a shared CNA signature in breast, lung, ovarian, and uterine carcinomas.A Pan-cancer PCA of copy number data from a balanced, random sampling of tumors of 15 tumor types from The Cancer Genome Atlas (TCGA). The average tumor PC
scores for each tumor subtype are shown. Pan-cancer PC1 scores primarily separate diploid from highly aneuploid tumors, while PC2 distinguished GBM from the
other tumor types (Appendix Fig S1A and B). Four tumor subtypes with similar PC scores are labeled as “Signature positive (+)”. Tumor type abbreviations are as
defined by TCGA: ovarian serous cystadenocarcinoma (OV), breast (BR), bladder urothelial (BL), and thyroid (TH) carcinoma (*CA), uterine corpus endometrial
carcinomas (UCEC), lung (LU), and head and neck (HN) squamous carcinomas (*SC), skin cutaneous melanoma (SKCM), lung (LU), rectal (RE), colon (CO), stomach (ST),
and prostate (PR) adenocarcinomas (*AD), glioblastoma (GBM), low-grade glioma (LGG), and kidney renal clear cell carcinoma (KIRC).
B Copy number profiles of 873 breast invasive carcinomas (BRCA). Tumors (rows) sorted by tumor-specific principal component 1 (PC1) score with genomic locations
listed across the top. PCA identified and distinguished two signatures with similar degrees of variance in the first component. The triangle marks the transition from
signature A through diploid samples to signature B. The membership of each tumor with known molecular subtypes (e.g., basal/luminal) and mutant TP53 status are
indicated on the right with red horizontal bars and corresponding permutation-based enrichment P-values. Basal and luminal subtype classifications are from a
published gene expression-based determination (The Cancer Genome Atlas Research Network, 2012b). Signature A was moderately enriched for claudin-low tumors,
whereas the HER2-enriched subtype was not significantly associated with either signature A or B (Fig EV2D). Similar PCA-based distinctions were observed in the LU,
OV, and UCEC datasets (Fig EV2A–C).
C Pan-cancer PC1 loadings and signature A summary profiles for ovarian (OV), breast (BRCA), uterine (UCEC), and lung (LU) tumor types. Summary signatures are
normalized gene loci signal-to-noise ratios (SNRs) of the top 10% of PC1-based core signature A tumors compared to normal (non-tumor) samples. Pan-cancer PC1-3
loadings are shown in Appendix Fig S1C. Consistency signatures of conserved amplification and deletions (consistent regions) are indicated by their signed absolute
minimum consistency score (SAMCS). The SAMCS is non-zero when all CNA summary signatures have the same sign across all tumor types, and is derived from the
absolute value-based minimum summary metric, and then re-signed positive for amplification or negative for deletion (see Materials and Methods). In the bar graph, red
and blue denote consistently amplified and deleted regions, respectively. The number or percentage of consistent regions, genome coverage, and gene loci are indicated.
The positions of canonical oncogenes, proto-oncogenes, tumor suppressor genes, and telomerase components (TERC, TERT) present in these regions are indicated.
D Breast signature A tumors have more DNA breakpoints per chromosome than signature B tumors, but similar levels of copy number alteration (as measured by an
integrated CNA score proportional to the extent and absolute value magnitude of amplifications and deletions). P-values are indicated (top, Mann–Whitney U-test;
bottom, Student’s t-test), and data presented in box (median, first and third quartiles) and whisker (extreme value) plots. The number of breakpoints is inversely
proportional to the mean DNA segment length.
E KEGG metabolism pathway enrichment analysis based on consistent CNA patterns in the core signature A tumors of (A). The OV, BRCA, UCEC, and LU signatures from
(C) were sequentially added and only directionally consistent CNA changes were retained (see Materials and Methods). The combined glycolysis–gluconeogenesis
(glycolysis) and pentose phosphate pathway was included based on our prior mRNA work identifying the predictive value of this gene set (Palaskas et al, 2011). Core
glycolysis is a KEGG-defined gene subset (M00001). Table EV1 lists enrichment results for all KEGG metabolism pathways.
F Schematic showing average signal-to-noise (SNR) metrics of core glycolysis pathway genes plus 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase (PFKFB and
TIGAR), lactate dehydrogenase (LDH), and pyruvate dehydrogenase (PDH) in core signature A tumors from (C) and (E). A more detailed listing of the gene names can
be found in Materials and Methods.
G Gene copy number alteration distributions of selected glycolysis genes, TIGAR, the tumor suppressor p53, and the p53-associated cancer genes MDM2 and CDKN2A in
BRCA tumors. Data are presented in box (median, first and third quartiles) and whisker (extreme value) plots.
Data information: In panels (C, E–G), the top 10% of tumors from each indicated signature based on PC1 scores were used in the analysis. See also Fig EV2 and
Appendix Figs S1–S3.
◀
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Using human tumors only, the sequential enrichment analysis
showed a general improvement through the addition of the COAD
tumor type (Fig 2A, dotted orange line; average enrichment signal
of the top 10 metabolic pathways). Moreover, sequential inclusion
of the corresponding tissue-matched mouse cancer model
CNA signatures substantially enhanced the overall pathway
enrichment results with the peak occurring at HNSC, a sequentially
adjacent tumor type that has similar pan-cancer PC1 score with
COAD (Fig 2A, solid blue line and arrow indicating the peak).
Overall pathway enrichment then decreased as additional, less copy
number similar (lower pan-cancer PC1 scores) tumor types were
added.
The improvement upon including the mouse signatures supports
the hypothesis that the cross-species analysis eliminates passenger
genes and reveals pathways whose genes are enriched in the result-
ing cross-species consistent CNA regions. Taken together, this pan-
cancer and cross-species analysis demonstrates that a combination
of nine human tumor types (OV, BRCA, UCEC, LU, BLCA, READ,
SKCM, COAD, and HNSC) and four corresponding mouse tumor
models (Brca, Blca, Skcm, and Coad) gives the strongest overall
enrichment signal strength across all metabolic pathways (Fig 2A).
Examining the highly ranked individual pathways from this opti-
mized tumor type combination, we found that the carbohydrate
metabolism pathway “amino sugar and nucleotide sugar metabo-
lism” (hsa00520) was ranked first and glycolysis–gluconeogenesis
(hsa00010, henceforth called glycolysis) was ranked second among
KEGG metabolism gene sets (Fig 2B and Table EV1). As in the aver-
age of top 10 pathways (Fig 2A), the enrichment score for the
glycolysis gene set improved as more human tumor and mouse
models were sequentially included up through the additions of
HNSC and Coad (Fig 2C). Compared to our previous enrichment
analysis of the four core signature A tumors (Fig 1E), the permuta-
tion P-value of the glycolysis gene set improved from 0.05 to 0.001,
reflecting that our pan-cancer and cross-species analysis has elimi-
nated passenger genes in the non-consistent CNA regions. Thus, we
hereafter refer to the consistent signature pattern from OV up
through and including HNSC and Coad as “expanded signature A”.
Of particular note, upon expanding our analysis to include 1,321
gene sets from the MSigDB Canonical Pathways (CP) database,
glycolysis remained a top result as the third ranked pathway, with
the “glutathione-conjugation” pathway (involved in cell detoxifi-
cation and oxidative stress responses) also scoring strongly (Fig 2B
and Table EV2).
To visualize the pan-cancer and cross-species conserved genomic
regions, we plotted the consistency profiles of the expanded signa-
ture A human and mouse tumors (Fig 2D). Examination of
conserved regions revealed that HK2, TPI1, GAPDH, PGAM2, ENO2,
and LDHB glycolysis genes contribute to the cross-species consis-
tency signal. Among canonical oncogenes, MYC and KRAS were also
present in the amplification regions of the expanded signature A
human tumors and mouse models. Due to the well-documented and
clinically relevant role of glycolysis and pentose phosphate path-
ways in tumorigenesis, we chose to further examine the recurrent
amplification of the set of these gene loci in subsequent analyses.
Equally important for functional validation of these candidate path-
ways, the activity of glycolysis can be directly and indirectly
measured by many assays in both patients (e.g., FDG-PET imaging)
and experimental systems.
CNA signatures are predictive of glycolysis
In that the CNA-consistent region-defined signature A is enriched
for core glycolysis genes, we next tested whether signature A patient
tumors in vivo were associated with increased tumor glycolysis. To
assign a signature A score to a set of FDG-PET-imaged breast
cancers (Palaskas et al, 2011), we projected CNA data from these
tumors onto a PCA of the four core human tumor tissue types (OV,
BRCA, UCEC, and LU, Fig 1C). We found a strong correlation
between the strength of CNA signature A and the measured FDG-
PET standardized uptake values (SUVs) (Fig 3A and B; Pearson
rho = 0.94, P = 5 × 105). A similar analysis using all nine
expanded signature A tumor types demonstrated equivalent results
(Appendix Fig S4A; Pearson rho = 0.92, P = 2 × 104). Thus, the
CNA-defined signature A is associated with increased FDG uptake in
human primary tumors in vivo.
We next asked whether the CNA signature A-defined tumors
associated with high FDG uptake also had RNA-based signatures of
increased glycolysis. First, we compared signature A tumors to
signature B tumors using RNA-based enrichment analysis (GSEA).
We analyzed both BRCA and LU tumors because these tumor types
show distinct signature A and signature B subtypes. (OV signature B
is highly similar to the pan-cancer signature A pattern, and thus
does not provide a differential test (Fig EV2B). UCEC tumors were
not included due to a lack of sufficient paired RNA and DNA profil-
ing data.) In the enrichment analysis, we included a gene set
consisting of genes from the glycolysis and pentose phosphate path-
ways that were upregulated in FDG-high BRCA tumors, as defined
by our previous work (Palaskas et al, 2011). In the GSEA, the
empirically defined FDG-high gene set ranked number one overall
(NES = 2.5, permutation P-value = 2 × 104), confirming that Sig A
tumors have glycolysis RNA expression profiles matching those of
FDG-high tumors (Fig EV4A). Furthermore, BRCA and LU signature
A tumors were significantly enriched for genes from the full glyco-
lysis and pentose phosphate pathways (overall rank 4th of 76 path-
ways, NES = 2.0, permutation P-value = 6.8 × 103), as well as
other glycolysis-related pathways (Table EV3). This analysis of RNA
expression data is consistent with the enrichment of glycolysis-
associated pathways at the DNA copy number level (Fig 1E and
2B), and points to glycolysis-related pathways as selection targets
for upregulation in signature A tumors.
To further explore the RNA expression data, we predicted the
glycolytic phenotypes of the core signature A tumor types (BRCA,
LU, and OV) using RNA-based weighted gene voting (WGV) (Golub
et al, 1999) and our previously defined FDG prediction model
(Palaskas et al, 2011). UCEC tumors were again excluded because
there were not a sufficient number of samples with paired RNA and
DNA data. We found that RNA-based predictions of high glycolysis
were associated with the signature A end of tumor type-specific
PC1 for BRCA and LU (Fig EV4B–D). Signature A tumors were
predicted to be significantly more glycolytic than signature B
tumors for BRCA and LU (P-values of 2.4 × 1017 and 5.7 × 1018,
respectively, Fig EV4E). There was no significant differential trend
in OV tumors, potentially because almost all of these tumors are
genomically unstable (integrated CNA scores > 0.2) and the signa-
ture B of OV is relatively signature A-like (Fig EV2B and
Appendix Fig S1D). The OV predictions were consistent with
predicted high glycolysis across all tumors (Fig EV4E). To control
ª 2017 The Authors Molecular Systems Biology 13: 914 | 2017
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for the general increase in glycolysis predictions at increased levels
of genomic instability, we also analyzed the correlation between
glycolysis predictions and PCA scores for several range windows of
integrated CNA scores. This analysis demonstrated that RNA-based
predictions of glycolysis were significantly correlated with PC1
scores in BRCA and LU tumors with high integrated CNA scores
(permutation P-value for BRCA and LU < 1 × 106 each, Fig EV4F).
Taken together, the DNA-defined signature A tumors exhibit
RNA expression patterns consistent with increased FDG uptake.
These RNA-based results support the more downstream activity-
based findings of elevated FDG uptake in signature A tumors
(Fig 3A and B).
Returning to the result of the CNA-defined signature A being
associated with increased FDG uptake in human primary tumors
in vivo, we next asked which sets of metabolic gene loci copy
number levels were most predictive of glycolytic phenotypes. We
performed a CNA-based weighted gene voting (WGV) analysis to
predict the glycolytic phenotypes of breast tumors and breast
cancer cell lines (Neve et al, 2006) using individual gene sets
from the KEGG metabolic pathways database (Kanehisa et al,
2014). Gene weights were calculated from each of our four tumor
type CNA “training” signatures. Specifically, we tested the ability
of individual metabolic pathways to predict (i) FDG uptake in
patient primary breast tumors and (ii) the lactate secretion of a
panel of 32 breast cancer cell lines (Hong et al, 2016). Averaging
results across these two test cases revealed that genes from the
glycolysis and pentose phosphate pathway were most predictive
of these metabolic phenotypes (Fig 3C and Table EV4; P = 0.01).
Moreover, signature A-based predictions were predictive of lactate
secretion for basal cell lines more so than for luminal lines
(Fig 3D and E, and Appendix Fig S4B), consistent with the
observed basal-type tumor enrichment in signature A samples
(Figs 1B and EV2D). Thus, consistent with the gene expression-
based predictions above, the glycolysis and pentose phosphate
pathway DNA copy number alterations from signature A are
predictive of glycolytic phenotypes of primary human breast
tumors and cancer cell lines.
Experimental recapitulation of tumor CNA signatures
Having demonstrated that the glycolytic pathway is statistically
associated with genome-wide DNA copy number patterns, we
sought an experimentally tractable system that would allow us
to test the hypothesis that recurrent patterns of DNA amplifi-
cation reflect metabolic selection pressures. We thus derived a
panel of immortalized mouse embryonic fibroblasts (MEFs) using
the classical 3T9 protocol (Todaro & Green, 1963). In this exper-
imental system, under standard culture conditions (e.g., 21%
O2), diploid cells undergo a crisis-associated event that increases
tolerance for genomic instability and allows them to escape
senescence and evolve into cells with chromosomal instability
and genomic aberrations (Fig 4A and Appendix Fig S5A; Sun &
Taneja, 2007). This system has been used to study core cancer
phenotypes such as proliferation, anti-apoptosis, and chromoso-
mal instability (Lowe et al, 1993; Gupta et al, 2007; He et al,
2007; Sotillo et al, 2007; Sun et al, 2007; Weaver et al, 2007)
and is one of the few experimentally tractable cancer models
involving spontaneous genomic instability (Sherr & DePinho,
2000). In addition, because this system is not driven by strong
oncogenes (e.g., KRAS mutation), it allows for complex CNA
signatures to evolve from a combination of individual, presum-
ably weaker, DNA alteration events.
We profiled the genome-wide copy number of 42 independent
MEF sublines by CGH microarray (Fig 4A). Most samples were pro-
filed after immortalization (post-senescence), with a few profiled
before or during senescence. Analysis of this CNA data by PCA
revealed that the MEF system recapitulated a two-signature pattern
(signatures A and B). These two signatures were generally orthogo-
nal, with the exception of a few “mixed” samples that had CNA
characteristics of both signatures A and B (Appendix Fig S5B). As
anticipated from prior MEF studies, immortalized MEF cells exhib-
ited an increased number of genomic breakpoints and a higher
degree of copy number alterations than the diploid, pre-senescent
MEF cells (Appendix Fig S5C and D). Importantly, the MEF-derived
signature A resembled the shared signature A pattern derived from
◀ Figure 2. Pan-cancer and cross-species analysis reveals enrichment of glycolytic genes in conserved amplification regions.A Average pathway enrichment signal strength for the top 10 enriched KEGG metabolism pathways based on the consistent CNA patterns across multiple tumor types.
The four core CNA signature A patterns are defined as in Fig 1C. CNA signatures for other tissue tumor types are defined by the signal-to-noise ratios (SNRs) of all
tumors compared to tissue-matched normal (non-tumor) samples. Starting with the four core signature A tumor types from Fig 1 (OV, BRCA, UCEC, and LU),
additional human (orange) or human and mouse (blue) signatures were sequentially added based on their decreasing tissue type pan-cancer PC1 score from Fig 1A
(see Materials and Methods). The resulting sequentially restricted consistency signatures are illustrated in (D). A maximal peak (indicated by an arrow) in the
enrichment signal of this sequential analysis is seen after adding tumors through human HNSC and mouse Coad (no mouse Hnsc signature was available).
Enrichment signal strength is based on the negative log frequency of equivalent enrichment by chance (i.e., permutation P-value). Mouse tumor type abbreviations
are shown with lower case letters but otherwise match the human TCGA abbreviations.
B Enrichment analysis of metabolism (75 KEGG pathways) and canonical pathways (CP; 1,321 MSigDB canonical pathways). Permutation P-values for the consistent
CNA patterns from the four human core signature A tumors (defined in Fig 1C), the human expanded signature A (from A), and the human expanded signature A
combined with corresponding mouse cancer models (from A). FDR calculations are described in Materials and Methods. Tables EV1 and EV2 list all sequential
enrichment results for KEGG metabolism and canonical pathways, respectively.
C Enrichment score for the glycolysis pathway upon sequential addition of human tumors and mouse models (as in A) showing a maximal peak in the enrichment
signal corresponding to the expanded HNSC–Coad signature.
D Genome view of the sequential consistency signatures used in the enrichment analysis of (A–C). The locations of consistently amplified glycolysis genes, canonical
oncogenes, and tumor suppressors are indicated. Genes listed in parentheses (i.e., RPIA, TERC, TERT, APC, and TP53) were consistently altered across the human tumors
but not consistently altered in the mouse models, due in part to the inclusion of p53 genetic knockout mouse models (TP53) and known differences in human and
mouse telomere maintenance (TERC, TERT) (Sherr & DePinho, 2000). The synteny graph at the bottom indicates the syntenic mouse chromosome number and thus
the broken synteny regions between human and mouse genomes. This genome view chronicles how the sequential pan-cancer and cross-species analysis of
conserved amplification and deletion loci greatly reduces the percentage of consistent copy number alterations, thereby reducing the percentage of the genome
implicated as candidate driver regions.
ª 2017 The Authors Molecular Systems Biology 13: 914 | 2017
Nicholas A Graham et al Tumor CNAs reflect metabolic selection Molecular Systems Biology
7
human breast, lung, ovarian, and uterine tumors. In particular, the
MEF-derived signature A was characterized by p53 mutation and
chromosome loss at the p53 locus, more genomic breakpoints,
subchromosomal-sized alterations, and a higher degree of copy
number alteration (Fig 4A and B, and Appendix Table S1). Addition-
ally, this experimental system allowed us to profile the same MEF
lines at subsequent passages, and a paired statistical analysis of five
evolving signature A lines revealed genomic regions changing from
mid- to late passage (Fig 4A and Appendix Fig S6A and B). Similar
to the shared human tumor signature A, both the MEF signature A
and the evolving MEF signature demonstrated DNA amplifications
of glycolysis and glycolysis-related genes (Table EV2). In particular,
both human and mouse CNA signatures A included amplification of
Hk2, Bpgm, Rpia, Tigar (mouse gene 9630033F20Rik), Eno2, Tpi1,
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Gapdh, Ldhb, Kras (mouse chr. 6), and Pgk2 (mouse chr. 17)
(Figs 1G and 4A, and Appendix Fig S6C).
In contrast, the MEF-derived signature B was characterized by
amplification of Mdm2 or deletion of Cdkn2a (Ink4a/Arf) and fewer
overall copy number alterations. Mdm2 amplification and Cdkn2a
loss are alternative mechanisms for inactivating p53 function in
human tumors and in MEFs (Sherr & DePinho, 2000), but as found
here result in a distinct CNA signature as compared to the p53 muta-
tion-associated signature A. As in human BRCA (Fig EV2E), amplifi-
cation of Mdm2 and loss of Cdkn2a were generally mutually
exclusive in signature B MEFs (Appendix Fig S6D), reflecting alter-
nate mechanisms for disabling the p53/ARF axis (Sherr & Weber,
2000). Additionally, Mdm2 amplification tends to co-occur with Hk1
amplification, both loci being located on mouse chr. 10. Thus, the
signature B cases are associated with an alternate HK amplification,
similar to our finding in signature B human tumors (HK1 or HK3
rather than HK2) (Fig 1G and Appendix Figs S2G and S6C).
Immunoblotting confirmed that signature A MEF and signature B
MEF lines generally had increased expression of Hk2 and Hk1
protein, respectively (Appendix Fig S6E and F).
To further characterize the association between p53 loss and
CNA signatures, we profiled the CNA patterns of 29 independent
p53/ MEF sublines derived in standard 3T9 culture conditions.
Comparison of the p53/ MEF CNA patterns to wild-type MEFs by
PCA demonstrated that the CNA patterns of p53/ MEFs resemble
the wild-type MEF signature A pattern, with no signature B-like
sublines observed (Appendix Fig S7). p53/ MEFs do not undergo
senescence (Olive et al, 2004), and consistent with this, we
observed that they tended to have less strong copy number alter-
ations. In summary, strong p53 functional loss (p53 mutation or
genetic loss) tends to lead to the CNA signature A pattern, which is
associated with a higher degree of copy number alterations (higher
integrated CNA score and more breakpoints) and Hk2 amplification,
while weaker or less complete p53 functional loss (e.g., mediated by
Mdm2 amplification or Cdkn2a loss) is associated with an alterna-
tive signature (signature B).
Numerical and structural chromosomal abnormalities
Next we sought to understand how CNA signatures revealed by
CGH relate to numerical and structural aneuploidy (i.e., whole chro-
mosomal and subchromosomal gains or losses, respectively). Using
propidium iodide-based DNA staining, we found that immortalized
MEF cells had increased total DNA content compared to pre-
senescent MEFs (Appendix Fig S8A–C). Similar results were
observed in a comparison between a genome-stable, close to
diploid, immortalized human mammary epithelial cell line
(MCF10A) and a human breast cancer cell line with a high degree of
DNA copy number alterations (Hs578T). In addition, we used spec-
tral karyotyping (SKY) to assess the numerical and structural chro-
mosomal aberrations in immortalized MEF cells. Profiling a
representative signature A MEF subline just after immortalization
(subline H1; passage 25, P25), SKY revealed increased total DNA
content (105  36 chromosomes) with nearly all chromosomes
having experienced whole chromosome gains (Appendix Fig S8D, E
and H). In addition, there was substantial cell-to-cell heterogeneity
in the number and type of chromosomes at passage 25. Profiling the
same MEF cell line 23 passages later (P48), SKY revealed that the
average number of chromosomes had slightly decreased and stabi-
lized (84  12 chr), as has been reported previously (Hao &
Greider, 2004), and clonal markers had begun to emerge (e.g.,
translocation (3:16)) (Fig 4C and Appendix Fig S8F, G and I). We
also observed a substantial number of double minutes in some of
the cells examined at P48. As expected, the most strongly amplified
chromosomes by SKY were scored as gains in CGH data (e.g., chrs.
3 and 6 in subline H1 at P48/49). Since array CGH analysis is
normalized by input DNA quantity, genomic regions scoring as
negative on a log2 CNA plot can be greater than diploid if most other
chromosomes have amplified to an even greater extent (e.g.,
trisomy chrs. 1, 2, and 7 in subline H1 at P48/49). Similar results
have been reported for karyotyping and CGH results of human
cancer cell lines (Kyto¨la¨ et al, 2000). Taken together, these data
reveal that immortalized MEFs experience substantial numerical
and structural chromosomal abnormalities, similar to what is
observed in human tumors, and further support that selection for
optimized rearranged genomes occurs.
Senescence-associated oxidative stress as a selective force for
copy number alterations
The MEF system allowed us to investigate the selective pressures
driving copy number changes during immortalization. Because
MEFs cultured under physiological oxygen conditions (3% oxygen)
undergo little to no senescence and exhibit less DNA damage
◀ Figure 3. PCA-based CNA signatures are predictive of breast cancer glycolytic metabolism in vivo and breast cancer cell line metabolism in vitro.A PC1-sorted copy number profiles of a balanced, random sampling of tumors from the four core CNA-consistent tumor types (breast, lung squamous, ovarian, and
uterine carcinomas, Fig 1A) along with copy number profiles from primary breast carcinoma tumors with glycolytic levels imaged in vivo by 18F-fluorodeoxy-
glucose positron emission tomography (FDG-PET) (Palaskas et al, 2011). On the right, red and green values indicate high and low FDG standardized uptake values
(SUVs), respectively, for FDG-imaged tumors.
B FDG uptake values in FDG-PET measured tumors are highly correlated with CNA signature A PC1 score (q, Pearson rho correlation; P-value = 5.3 × 105).
C CNA values for genes from glycolysis and pentose phosphate pathways have stronger predictive power of FDG-PET SUV in breast tumors and of lactate secretion
(sec.) in breast cancer cell lines than other metabolism pathway-based sets of genes. The table indicates the correlation between weighted gene voting (WGV)-
based predictions on the test sets and the measured metabolic phenotypes. WGV was performed with individual training on signature A tumors from each of the
core four tumor types (breast (BRCA), lung (LU), ovarian (OV), and uterine (UCEC); top 10% signature A compared to normal (non-tumor) samples), the voting
predictions were averaged, and compared to the measured metabolic phenotype. P-values were assessed by permutation analysis. See Table EV4 for all pathways.
D, E Signature A-based WGV predictions and signature A-based PC1 projections (as in B) have stronger correlation with measured lactate secretion for basal-like breast
cancer cell lines than for luminal-like lines (D). See Appendix Fig S4B for luminal cell line data. Basal and luminal subtype classifications are from a published gene
expression-based determination (Neve et al, 2006). The breast cancer-based glycolysis and pentose phosphate pathway (G & PP) WGV predictions are shown as a
representative case (E).
Data information: See also Appendix Fig S4B.
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(Parrinello et al, 2003), we tested whether oxidative stress-induced
senescence is a selective pressure for copy number alterations. To
protect cells from oxidative stress, we cultured MEFs in 3% oxygen
in media supplemented with or without catalase, an enzymatic scav-
enger of reactive oxygen species (ROS) (Halliwell, 2003; Graham
et al, 2012). When doubly protected from oxidative stress, MEFs did
not undergo senescence and maintained relatively diploid genomes
(Fig 4A and Appendix Fig S5A). In addition, we observed a varia-
tion in the degree of senescence experienced by MEFs derived in
atmospheric oxygen concentrations (21%) (Appendix Fig S5A).
Upon calculating the degree of senescence encountered by each
subline (senescence metric described in Materials and Methods), we
found a correlation between senescence and the degree of copy
number alterations (Fig 4D, Spearman rho = 0.66, P = 3 × 108;
and Appendix Fig S9A). Furthermore, p53/ cells did not undergo
senescence (Olive et al, 2004) and exhibited less strong copy
number alterations than wild-type signature A MEFs (Appendix Fig
S7B; P = 9 × 104). Taken together, our results implicate senes-
cence-associated redox stress as one of the selective forces driving
the copy number alterations recurrently observed in human tumors.
MEF CNA signatures recapitulate recurrent patterns from human
tumors and further implicate the glycolysis pathway in shaping
the cancer genome
Our pan-cancer and cross-species analysis revealed that the glyco-
lysis pathway is highly enriched in conserved CNA regions (Fig 2).
Because the MEF signature A is qualitatively similar to the human
expanded signature A, we next asked how inclusion of our MEF
signatures would affect metabolic and canonical pathway enrich-
ment analysis. Although the MEF immortalization system utilizes
fibroblast cells and the mouse tumors are epithelial in origin, both
types of models share a similar cross-species consistency with the
expanded signature A tumor types (Appendix Fig S9B). When the
human tumors signatures were combined with the MEF signatures,
consistent genome regions were reduced to 3.6% of the genome
spread over 13 conserved regions (Fig 4E). In cross-species pathway
enrichment analysis, MEF CNA signatures added a similar amount
of enrichment signal to human tumor signatures as do the non-MEF
mouse model signatures, and when combined together, the enrich-
ment was even stronger (e.g., glycolysis and core glycolysis
pathways, Fig 4F). When all signatures are used, glycolysis was the
top-ranked enriched pathway out of 1,321 MSigDB canonical
pathways (Table EV2). Thus, including the MEF signatures in the
cross-species analysis further implicates the glycolysis pathway in
shaping the cancer genome.
Examination of the cross-species genomic regions conserved in
human tumors, mouse models of cancer, and the MEF immortaliza-
tion system revealed consistent amplification of five regions
containing the COSMIC database-enumerated oncogenes GATA2
(human chr. 3; Fig 4E, last SAMCS line), TRRAP (chr. 7, region 4),
MYC (chr. 8, region 1), CHD4 (chr. 12, region 1), and KRAS (chr. 12,
region 2) (Forbes et al, 2015). Notably, four of the cross-species
conserved CNA genomic regions included genes from the glycolysis
◀ Figure 4. A mouse embryonic fibroblast (MEF) immortalization system recapitulates the two-signature CNA patterns and glycolysis gene CNA enrichmentobserved in human tumors and mouse models.
A Top: Copy number profiles of 59 samples from 42 independent mouse embryonic fibroblasts (MEF) sublines before, during, and after senescence recapitulate the two-
signature CNA patterns observed in human tumors. Twenty-two sublines evolved to Sig. A patterns, 13 sublines exhibited Sig. B, and seven sublines remained diploid-
like due to redox protection. PC1 scores for analysis of only signature A MEFs (PC1-Sig A), only signature B MEFs (PC1-Sig B), or all MEFs (PC1-Sig AB) are indicated on
the left. Also indicated are a metric of the degree of senescence observed during immortalization (senescence score), protection by 3% O2-based hypoxia or catalase
(+), or both (++) during immortalization, CNA profiling at passage 1 (P1), exogenous MYC expression (which enabled cells to bypass senescence), and Trp53
sequencing status (* indicates a non-severe mutation p.183D > E, blank indicates not sequenced, additional p53 sequencing information in Appendix Table S1).
Signature A MEF lines profiled at more than one passage number are indicated by the start (earlier passage) and end points (later passage) of the upward “evolving
signature A” arrows. For comparison to (C), the early (25) and late (49) passages of the H1 subline that were characterized by spectral karyotyping (SKY) are indicated
on the left by triangles. The indicated chromosome 6 region includes loci for Bpgm, Hk2, Rpia, Eno2, Tpi1, Gapdh, Tigar, Ldhb, and Kras. Bottom: Summary signatures of
amplification and deletion loci in copy number profiles (normalized PC1 loadings) are shown for MEF WT and p53/ signature A (Sig. A) samples. A paired t-test
analysis of signature A MEF lines profiled at more than one passage number revealed genomic regions associated with mid- to late-passage CNA evolution (log10 t-
test P-value signed positive for amplifications, negative for deletions; labeled “Evolving”). Individual profiles of p53/ signature A samples are not shown.
B Signature A MEFs have more DNA breakpoints and a larger degree of copy number alteration (integrated CNA score) than signature B MEFs. Signature A MEFs had a
subset of cases with large numbers of breakpoints per chromosome (> 10) that were not observed in the signature B MEFs (hypergeometric P-value = 0.02, Student’s
t-test P-value = 4 × 105). Data are presented in box (median, first and third quartiles) and whisker (extreme value) plots.
C Spectral karyotyping (SKY) of the H1 MEF subline at passage 48. Whole chromosomal gains of varying extent are observed for all chromosomes with some
chromosomes experiencing translocation, for example, t(3:16), and deletion, for example, del(4). Additional chromosome spreads and a summary table for P25 and
P48 karyotypes are shown in Appendix Fig S8. CGH profiles for H1 cells are in (A) (indicated by the triangles in the SKY column) and Appendix Fig S6A and B.
D The amount of senescence demonstrated during MEF line derivation (senescence score, see Materials and Methods) is highly correlated with the degree of copy
number alterations obtained (integrated CNA score) (Spearman rho = 0.66, P-value = 3 × 108). Single protection indicates protection by 3% O2 culture conditions or
media supplementation with 250 U/ml catalase. Double protection indicates that cells were cultured at 3% O2 with catalase.
E Conserved amplification and deletion loci in copy number profiles across core and expanded signature A human tumor types (Hs Sig. A), corresponding mouse
tumorigenesis model signatures (Mm models), and the MEF immortalization system (MEF Sig. A). The human and mouse signatures are as defined in Fig 2, and the
wild-type MEF signatures are from (A). In the human consistent regions, the 52.3% consistently altered gene loci include bona fide tumor suppressor genes (p53),
oncogenes (MYC, KRAS), telomere components (TERC, TERT), and core glycolysis genes (e.g., HK2). As in Fig 2D, genes listed in parentheses were consistently altered
across the human tumors but not consistently altered in the mouse. The tissue-specific, non-lymphoid oncogenes from the COSMIC database that are in a conserved
amplification or deletion region (TRRAP, CHD4) are listed for completeness (Forbes et al, 2015).
F Enrichment signal strength (negative of log permutation P-value) for the glycolysis and core glycolysis gene sets improve when MEF CNA signatures are added to the
human and mouse CNA signatures from Fig 2. The degree of increased enrichment upon addition of the MEF signatures is quantitatively similar to adding mouse
tumorigenesis model signatures. Adding all signatures into the analysis further strengthens the enrichment (last column). Table EV2 lists results for the enrichment
analysis of the remaining MSigDB canonical pathways when human core and expanded signature A, mouse models, and MEF immortalization models are
sequentially combined.
Data information: See also Appendix Figs S5–S9.
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pathway: HK2 (chr. 2), GCK and PGAM2 (chr. 7, region 1), ENO2,
TPI1, and GAPDH (chr. 12, region 1, which includes TIGAR), and
LDHB (chr. 12, region 2, which also includes KRAS). In both human
tumors and the MEF immortalization system, the genomic region
harboring TIGAR–GAPDH–TPI1–ENO2 was separated from the
LDHB–KRAS region by a deletion-prone region that includes the
tumor suppressor CDKN1B (Appendix Fig S9C–E).
To investigate whether amplification of the DNA cross-species
conserved CNA regions results in upregulated RNA expression
levels, we examined the correlation between DNA copy number and
RNA expression levels in BRCA, LU, and OV tumors for glycolytic
genes and, as a point of comparison, known oncogenes
(Appendix Fig S10). We examined the average correlation across
BRCA, LU, and OV signature A tumors for all genes in the 12 cross-
species conserved regions. We found that three glycolytic genes
(LDHB, TPI1, and GAPDH) and one oncogene (KRAS) exhibited
strong DNA–RNA correlation (r > 0.66), three glycolytic genes
(HK2, ENO2, and PGAM2) and three oncogenes (MYC, CHD4, and
TRRAP) exhibited moderate correlation (0.2 < r < 0.5), and only
one glycolytic gene (GCK) and one oncogene (GATA2) exhibited
weak DNA–RNA correlation (r < 0.2) (Appendix Fig S10A and B).
This analysis indicates that gene copy number alterations at the
DNA level generally lead to increased RNA expression in signature
A tumors in BRCA, LU, and OV tumors, with a similar degree of
correlation observed for both glycolysis genes and oncogenes.
Finally, we compared the upregulation of glycolytic genes and onco-
genes on two cross-species conserved regions of human chr. 12 that
contain both types of genes (Appendix Fig S10C). Within the centro-
mere-distal region of chromosome 12, the glycolytic genes TPI1 and
GAPDH show strong correlation (Spearman rank correlation = 0.71
and 0.66, respectively) while the oncogene CHD4 and the glycolytic
gene ENO2 exhibit moderate correlate (Spearman rank correla-
tion = 0.42 and 0.32, respectively). Within the more centromere-
proximal region, LDHB and KRAS both exhibit strong correlation
(Spearman rank correlation = 0.68 and 0.66, respectively). Impor-
tantly, the correlation of RNA expression with DNA amplification is
not stronger for oncogenes than for glycolytic genes within these
cross-species regions. Taken together, these results support a model
in which the selection pressures shared during immortalization and
tumorigenesis result in cross-species conservation of the glycolysis
gene loci copy number alterations (Fig 4E and F, and Table EV2).
Alteration of CNA signatures by exogenous expression of
metabolic enzymes
The presence of core glycolysis genes in cross-species conserved
amplification regions suggests that these metabolic gene loci drive
the amplification of these regions. To test this hypothesis, we trans-
duced pre-senescent MEFs with either wild-type HK2 or HK1,
kinase-dead HK2 (D209A/D657A) (McCoy et al, 2014), or wild-type
ENO2 and allowed the cells to senesce and immortalize in the pres-
ence of these exogenously expressed proteins (Appendix Fig S11).
Analyzing the signature A set of sublines, we found that the endoge-
nous Hk2 locus (chr. 6) was less amplified in cells expressing exoge-
nous wild-type hexokinase (P = 0.048) (Fig 5A and B). As a control,
a signature A MEF cell line expressing kinase-dead hexokinase
did not show reduced amplification of the Hk2 locus (P = 2 ×
104). In that MEF lines exogenously expressing hexokinase still
demonstrated positive selection for the centromere-proximal half of
chr. 6 (Fig 5A), we examined the ratio of Hk2 gene locus copy
number to the maximal amplification on chromosome 6 (Hk2:Chr6
max). In this analysis, we found that cells expressing exogenous
hexokinase demonstrated significantly reduced Hk2:Chr6 max ratios
(P = 3 × 103) (Fig 5A and C). Additionally, a MEF subline express-
ing exogenous ENO2 exhibited deletion rather than amplification of
the Eno2 locus on chr. 6 (P = 0.02) (Fig 5A and D). Analyzing the
signature B set of sublines, we found that the endogenous Hk1 locus
(chr. 10) was copy number neutral, rather than amplified, in a cell
line expressing exogenous hexokinase (P = 0.17), whereas a signa-
ture B MEF cell line expressing kinase-dead hexokinase did not
show reduced amplification of the Hk1 locus (Fig 5E and F).
Fisher’s combined statistical analysis of these results yielded
P-values of 0.001 or less (Fig 5).
Taken together, these results demonstrate that exogenous
expression of metabolic enzymes can alter the copy number status
of the endogenous genomic loci, supporting these metabolic genes
as drivers within the conserved amplification regions observed in
human tumors and mouse models. In addition, these results support
a model in which the net propensity for a chromosomal region to
be amplified or deleted is in part related to the sum of the fitness
effects of the genes present (Davoli et al, 2013). For example, when
HK2 is exogenously expressed, the centromere-distal half of
chromosome 6 had a low copy number value in early culture but
after additional culture demonstrated increased copy number,
supporting that the other gene loci of this region (such as Eno2,
Gapdh, and other glycolytic genes) do have a remaining pro-fitness
benefit (Fig 5A).
Metabolism and growth phenotypes of CNA signatures
To test whether there exist phenotypic differences between signa-
ture A and signature B MEFs, we characterized 11 wild-type MEF
lines representative of either signature A or B and one mixed signa-
ture line. We found that signature A MEFs generally had higher
rates of glucose consumption and lactate production than signature
B MEF lines (Figs 6A and EV5F). Plotting the PC1 score versus
glucose consumption, we found that CNA-based signature A was
highly predictive of glucose consumption in the MEF signature A
lines (Fig 6B). In contrast, signature B was only moderately predic-
tive of the glucose consumption of signature B lines, and was not as
accurate as signature A in predicting the glucose consumption of
signature A lines (Figs 6B and EV5A). In addition, we noted that the
signature A cell lines generally exhibited significantly higher rates of
proliferation than the signature B cell lines (Fig 6C). Similar to
glucose consumption, signature A was predictive of the growth rates
of signature A MEFs and signature B was predictive of the growth
rates of signature B MEFs, while cross-signature predictions had less
power (Figs 6D and EV5B). Furthermore, we observed a general
coevolution of higher growth rates and increased CNA signature
strength in MEF lines that were profiled at different passage
numbers (Fig 6D). As noted above, the evolving MEF CNA signature
pattern was enriched for DNA amplifications of genes in the core
glycolysis and glycolysis-associated pathways (Table EV2), particu-
larly due to amplification of chromosome 6, which contains multiple
metabolic gene loci including Hk2 and Eno2 (Fig 4A and E, and
Appendix Fig S6B).
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To test whether signature A and signature B MEFs differentially
use glucose, we cultured MEF cells with [1,2-13C]-labeled glucose
and conducted metabolomic profiling by mass spectrometry
(Fig EV5C–G and Table EV5) (Metallo et al, 2009). In all MEF lines
tested, we observed a low percentage of single heavy labeled carbon
[M1 isotopomer compared to M2] in pyruvate, lactate, and alanine,
indicating that the contribution of glucose-derived carbon from the
oxidative arm of the pentose phosphate pathway to these metabo-
lites was relatively low (Fig EV5D). Nonetheless, the patterns of
heavy isotope labeling revealed differences in nutrient utilization
between signature A and B MEF cell lines. On average, metabolites
of early glycolysis, the pentose phosphate, and nucleotide synthesis
pathways showed a higher percentage of glucose-derived heavy
carbon labeling in signature A MEFs (Figs 6E and EV5E). In
contrast, signature A cells had a lower percentage of glucose-derived
heavy carbon labeling in metabolites of the serine synthesis path-
way and the TCA cycle. When compared to signature B MEFs,
signature A cells also tended to exhibit increased consumption of
serine, glutamine, and other amino acids (Fig EV5F and G). The
increased glutamine consumption in signature A MEFs reflects
similarity with basal breast cancer cell lines (also signature A associ-
ated), which exhibit increased glutamine consumption relative to
luminal breast cancer cell lines (Timmerman et al, 2013). In
general, the percentage of individual metabolites from the early
glycolysis, the pentose phosphate, and nucleotide synthesis path-
ways that incorporated heavy, glucose-derived carbon metabolites
was positively correlated with glucose consumption rates (e.g., fruc-
tose-1,6-bisphosphate, Fig 6F). Conversely, metabolites from the
serine synthesis pathway and the TCA cycle showed a negative
correlation between glucose consumption rates and the percentage
of each molecule containing a heavy, glucose-derived carbon (e.g.,
3-phosphoserine, Fig 6F). While caution must be exercised when
interpreting metabolite labeling results, we overall observed a
consistent trend of differences between signature A and B lines. Of
note, the differences between signature A and B lines were mainly
in regard to scale, with the strongest signature B lines demonstrating
similar glycolysis and proliferation rates, as well as similar meta-
bolic profiles, as the weakest signature A lines.
Taken together, these results demonstrate that signature A MEFs,
which resemble signature A human tumors, exhibit increased
glycolysis and to a somewhat lesser extent increased proliferation,
and have an increased relative proportion of glucose-derived carbon
in metabolites of pentose phosphate-associated biosynthetic path-
ways such as nucleotide synthesis. These findings are consistent
with published mouse model studies in which tumor cells that are
channeling glucose toward nucleotide biogenesis achieve faster
rates of proliferation (Boros et al, 1998; Ying et al, 2012).
Thus, our cross-species and pan-cancer CNA analysis revealed
conserved amplification regions shared by the majority of tumor
types studied that are enriched for genes involved in core glycolysis.
To aid others in pan-cancer and cross-species CNA signature
comparisons, we have created an interactive web-interface resource
available at http://systems.crump.ucla.edu/cna_conservation/.
Discussion
Chromosomal instability and high glycolysis characterize some of
the most aggressive tumors, and the complexity and plasticity of the
genomes in aggressive tumors can hinder molecularly targeted
therapies (Nakamura et al, 2011; McGranahan et al, 2012; Shi et al,
2012). While the glycolytic changes associated with tumorigenesis
were one of the early defining phenotypes of cancer cells (Warburg,
1956), they have not previously been linked to recurrent DNA copy
number patterns. Taken together, our experimental and computa-
tional data support a model in which glycolysis-linked selective
pressures encountered during tumorigenesis (e.g., redox stress and
senescence) shape the highly recurrent DNA copy number alter-
ations found in aneuploid human tumors (Fig 6G). We found that
CNAs in core glycolysis enzymes (e.g., HK2) and other cancer-
linked metabolic enzymes such as TIGAR are coordinately enriched
in tumors with distinct CNA signatures. These CNA signatures are
predictive of glycolysis, including patient FDG-PET activity and cell
line proliferation phenotypes. The strong correlation of CNA-based
principle component scores to uptake of the glucose analogue FDG
in breast cancer patients and the predictive power of CNA signatures
for breast cancer cell metabolism (Fig 3) provide support that the
CNAs affecting metabolic gene loci collectively act as a copy
number-based driver of metabolic differences. Importantly, in that
exogenous expression of hexokinase and enolase enzymes reduced
▸Figure 5. Alteration of CNA signatures by exogenous expression of metabolic enzymes.A CD1 MEFs expressing exogenous HK1/HK2 or ENO2 exhibit reduced amplification of the endogenous Hk2 or Eno2 loci, respectively. Chr. 6 copy number profiles
from control signature A MEFs (untransduced or expressing red fluorescent protein (RFP)) compared to signature A MEFs expressing either wild-type HK1 or HK2,
kinase-dead HK2 (HK2 KD, D209A/D657A), or wild-type ENO2. The positions of endogenous Hk2 and Eno2 are indicated. MEF lines profiled at more than one
passage number are indicated by the start (earlier passage) and end points (later passage) of the arrows under “Evolving MEFs”.
B–D Boxplots of Hk2 copy number (B), ratio of Hk2 copy number to maximum amplification of chromosome 6 (defined operationally as the 5th percentile CNA value
across chr. 6 to avoid outlier effects) (C), and Eno2 copy number (D). Control MEFs: untransduced (squares) or expressing RFP (diamonds); test MEFs expressing
wild-type HK1 (upside-down triangles), HK2 (triangles in B and C), kinase-dead HK2 (HK2 KD, D209A/D657A, circles), or wild-type ENO2 (triangle in D). In this
analysis, copy number data from samples profiled at multiple passages were averaged to prevent overrepresentation of these cell lines. P-values were calculated
using Student’s t-test (B), Mann–Whitney U-test (C), and z-score (B, C) based on criteria described in Materials and Methods. Data are presented in box (median,
first and third quartiles) and whisker (extreme value) plots.
E Signature B MEFs expressing exogenous HK2 exhibit less amplification of the Hk1 locus. Chr. 10 copy number profiles from control signature B MEFs (untransduced
or expressing RFP) compared to signature B MEFs expressing wild-type HK2 or kinase-dead HK2 (HK2 KD). The positions of endogenous Hk1 and Mdm2 are
indicated.
F Boxplot of the Hk1 copy number with indicated P-value (z-score). Data are presented in box (median, first and third quartiles) and whisker (extreme value) plots.
Data information: Fisher’s combined P-values for the alteration of endogenous loci CNA by exogenous expression of metabolic enzymes is 3 × 105 (panels B, D, F) or
7 × 104 (panels C, D, F). For all comparisons in this figure, no significant differences were observed between untransduced and RFP-expressing MEFs. See also
Appendix Fig S11.
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the propensities for amplifications of the corresponding endogenous
hexokinase and enolase loci, these metabolic genes empirically
score as driver loci. However, we cannot exclude the possibility that
the observed metabolic differences are in part due to other cancer-
associated regulatory changes such as epigenetic events known to
affect metabolism (Sebastia´n et al, 2012). Combined with the obser-
vation that metabolic genes can facilitate cellular immortalization
(Kondoh et al, 2005; Kondoh, 2009; Kaplon et al, 2013), our results
implicate tumor metabolism as an additional fitness measure linked
to how genomic instability can enable tumorigenesis.
Chromosomal instability and aneuploidy—positive and negative
impact on tumor cell fitness
Most solid human tumors exhibit both numerical and structural
aneuploidy (Holland & Cleveland, 2012). Paradoxically, chromoso-
mal instability can act either as an oncogene or as a tumor suppres-
sor depending on the context (Weaver et al, 2007). Moreover,
addition of a single chromosome in MEF cells induces a stress
response that impairs proliferation and immortalization (Williams
et al, 2008). However, numerical aneuploidy can lead to chromoso-
mal instability (Nicholson et al, 2015) which results in subchromo-
somal gains and losses as observed in human tumors, in mouse
models of cancer, and in immortalized MEF cells. Thus, aneuploidy
can cause an initial fitness loss due to the costs of dealing with
non-optimized chromosome numbers, gene copy numbers, and
resulting proteomic imbalances. However, the associated state of
chromosomal instability enables further evolution of the genome
toward fitness gains through refinement of gene copy number
levels. In sum, these fitness gains either outweigh or offset the fit-
ness losses due to aneuploidy. In this context, our data support a
model (Fig 6G) in which metabolic selection forces and metabolic
gene loci contribute to the recurrent patterns of DNA copy number
alteration observed in human tumors.
Redox stress, biomass accumulation, and associated glycolytic
changes in tumorigenesis
Tumorigenesis is a complex, multistage process during which cells
must acquire the capability to maintain redox balance while accu-
mulating the macromolecular precursors required for proliferation
(DeBerardinis et al, 2008; Hanahan & Weinberg, 2011). Numerous
stimuli, including RAS mutations, matrix detachment, altered meta-
bolism, and hypoxia, induce the accumulation of intracellular ROS
(Lee et al, 1999; Schafer et al, 2009; Weinberg et al, 2010;
Anastasiou et al, 2011). Because increased ROS levels can trigger
replicative senescence and subsequent cell cycle arrest (Lee et al,
1999; Takahashi et al, 2006), tumors must maintain pools of
reduced glutathione using NADPH in part produced via the pentose
phosphate pathway. Additionally, increased levels of ROS can divert
glycolytic flux into the pentose phosphate pathway through, for
example, oxidation and inhibition of the glycolytic enzyme PKM2,
thereby supplying cells with the reducing power and precursors for
anabolic processes (Boros et al, 1998; Anastasiou et al, 2011).
▸Figure 6. Signature A and B MEFs exhibit differential metabolic and proliferation phenotype strengths.A PCA-defined signature A MEFs exhibit higher glucose consumption rates than signature B MEFs (Student’s t-test P-value = 0.009). Glucose consumption was
measured using a bioanalyzer.
B PC1 scores of signature A MEFs are predictive of glucose consumption rates in signature A MEFs, while scores from signature B MEFs have weaker predictive power in
signature B MEFs. In cross-prediction tests, signature A-based predictions of signature A MEF line metabolic phenotypes perform the best (Fig EV5A). Glucose
consumption was measured using a bioanalyzer.
C PCA-defined signature A MEFs exhibit higher average growth fold change, as observed in 3T9 culture, compared to signature B MEFs. Signature A MEFs had a subset
of cases with high growth rates (average fold change in cell number per passage > 4) that were not observed in the signature B MEFs (hypergeometric P-value =
0.02).
D Correlation and a general coevolution of higher growth rates and increased CNA signature strength. Arrowed lines indicate progressing MEF lines profiled at more
than one passage number (Appendix Figs S6A and B, and S9A). In cross-prediction tests, PC1 scores of signature A MEFs are more predictive of average growth fold
change in signature A MEFs, while scores from signature B MEFs are more predictive in signature B MEFs (Fig EV5B).
E Metabolomic profiling of 11 wild-type MEF lines representative of either signature A or B cultured for 24 h with [1,2-13C]-labeled glucose. The metabolic pathway
schematic is colored based on differences observed in the percent heavy label for intracellular metabolites (defined as percent of metabolite molecules with
isotopomer mass greater than the monoisotopic molecular weight, M0) between signature A and B MEFs using the signal-to-noise (SNR) metric. Red indicates a
higher heavy carbon-labeling percentage in signature A MEFs, and blue indicates a higher heavy carbon-labeling percentage in signature B MEFs. Signature A MEF
lines incorporate more glucose-derived carbon in metabolites from the early glycolysis steps, the pentose phosphate pathway, and nucleotide synthesis, and a smaller
fraction of glucose-derived carbon per molecule in metabolites from the later glycolysis steps, the serine synthesis pathway, and the TCA cycle. Full metabolomic data
can be found in Table EV5.
F Correlation of fructose-1,6-bisphosphate (F1,6BP) and negative correlation of 3-phosphoserine (pSer) with glucose consumption rates. Note, the high to low range for
percent metabolite molecules with incorporated label varies for each metabolite, but generally does not extend from 0 to 100%. Signature A and B MEFs are colored
red and blue, respectively.
G Model of copy number selection and fitness gains during tumorigenesis. Genomic instability enables fitness gains in tumor metabolism. In human tumors, cancer cell
lines, and an experimental MEF immortalization system, immortalization and tumorigenesis lead to multiple CNA signatures that are predictive of the tumor
phenotypes of metabolism and proliferation. Senescence-associated redox stress and other tumorigenesis-related constraints select for stronger CNA signatures. A
shared high glycolysis-associated signature A is observed in breast, lung, ovarian, and uterine tumors, additional tumor types, mouse models, and the MEF model
system, and is linked with a higher range of glycolysis and proliferation phenotypes. Genetic manipulation of glycolysis enzymes leads to alteration of corresponding
CNA signature propensities. Signature A and B genomes reflect two distinct trajectories from diploidy to tumor aneuploidy. Signature A tumors are enriched for
mutations in p53 and have smaller sized amplification and deletion genomic regions (i.e., have a higher number of genomic breakpoints), potentially providing
increased alternative genome options. Signature A involves amplification of several genes in glycolysis-related pathways (such as HK2, TIGAR, TPI1, GAPDH, ENO2, PGAM2,
and LDHB). Signature B CNA patterns occur in generally less glycolytic and proliferative samples and show more variation across different tumor types. In particular,
signature B is enriched forMDM2 amplification and CDKN2A loss, strong MYC amplification, and KRAS mutation and involves alternate hexokinase isoforms (HK1, HK3).
Data information: Data in (A, C) are presented in box (median, first and third quartiles) and whisker (extreme value) plots. Error bars indicate standard deviations of
biological replicates in (A, B, C and F). See also Fig EV5.
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Consistent with this published knowledge on the role of metabolism
in tumorigenesis, our study suggests that the metabolic stress asso-
ciated with senescence (Fig 4A and D) and the metabolic demands
of rapid proliferation (Fig 6) are components of the selective
pressures underlying recurrent CNA changes.
Experimentally and computationally deciphering CNA patterns
Our experimental and bioinformatic approaches complement exist-
ing approaches for testing hypotheses for the selection pressures
underlying recurrent CNA patterns observed in human tumors.
Other CNA-analysis approaches target different resolutions of the
genome. Statistical algorithms such as GISTIC (Genomic Identifi-
cation of Significant Targets in Cancer) have identified many strong
individual driver genes and candidate regions (Mermel et al, 2011).
Integrating CNA data with RNA knockdown screens and gene
expression data has further identified driver genes missed by statisti-
cal analysis of CNA data alone (Sanchez-Garcia et al, 2014). RNA
knockdown-based analyses have also been used to support a more
systems-level model in which the selection for amplification and
deletion of a particular DNA region is based on the cumulative
effects of many positive and negative fitness gains from multiple
genes within that genomic region (Solimini et al, 2012; Cai et al,
2016). Subsequent computational extensions have incorporated
somatic mutation patterns to infer the cumulative impact of co-
localized genes on fitness, and to successfully predict whole
chromosome and chromosome-arm resolution-level CNAs (Davoli
et al, 2013).
Our approach using phenotypic data, functional gene sets, and
cross-species syntenic mapping has yielded additional insight into
the selective pressures shaping tumor CNA patterns, namely coordi-
nated alteration of genes involved in glycolytic metabolism. Incor-
poration of copy number data from genetically engineered mouse
models allowed synteny constraints to substantially reduce passen-
ger amplifications and define a minimal collection of stringently
conserved copy number regions. Additionally, to our knowledge,
our experimental approach is the first reported system in which
CNA and associated phenotypes have been followed and repeatedly
sampled as non-immortalized cells undergo spontaneous genomic
instability and proceed from a diploid state to an immortalized
aneuploid state. Using this approach, we were able to validate
genomic regions that are (i) associated with increased glycolysis
and to a lesser but significant extent proliferation, (ii) enriched for
genes from the core glycolysis pathway, and (iii) conserved in both
human tumors and mouse models of cancer. Metabolic pathways
are known to be coordinately regulated by modest changes in
mRNA expression of functionally related genes (Mootha et al, 2003;
Palaskas et al, 2011). The coordinated alterations of metabolic
genes at the DNA level adds an additional mechanism, namely
conserved sets of CNA changes, by which glycolysis is dysregulated
to promote tumorigenesis.
A strength of our PCA-based approach is the ability to unbiasedly
reveal distinct CNA subsignatures within a tumor type. Observed
subsignatures, confirmed using an independent clustering analysis,
were found to be associated with previously known pathology- or
profiling-defined tumor subtypes (e.g., basal/luminal CNA signa-
tures in BRCA) (Bergamaschi et al, 2006) (Figs 1B and EV2A–D).
Across multiple tumor types, loss of p53 function through p53
mutation is associated with the high breakpoint signature A pattern.
In contrast, loss of the p53/ARF axis via other mechanisms (MDM2
amplification or CDKN2A deletion) in BRCA human tumors is asso-
ciated with a different CNA signature (signature B) that in general
has fewer breakpoints. In our experimental follow-up, the MEF
system recapitulated a two-signature pattern. Notably, the two
mouse signatures and their associated phenotype strengths were
defined by the initiating loss of tumor suppression event, namely
Trp53 mutation versus either Mdm2 amplification or Cdkn2a loss.
Thus, while the consequences of TP53 mutation and “MDM2 ampli-
fication/CDKN2A loss” are considered functionally similar and
therefore mutually exclusive (Wade et al, 2013), our findings indi-
cate they are not fully equivalent in terms of genomic instability and
subsequent metabolic evolution. The tolerance of more highly
disrupted and rearranged genomes upon p53 mutation appears to
allow more flexibility in the evolution of aneuploid cancer genomes,
thereby resulting in stronger glycolysis and somewhat enhanced
proliferation. The specific combinations of CNA changes occurring
in enzyme isoforms defining a metabolic pathway may be consid-
ered “onco-metabolic isoenzyme configurations” with differential
potency, and the sets of combinations possible may be limited
in part by the degree or specifics of tolerance to genomic re-
arrangements.
In summary, our work illustrates the value of cross-species
comparisons in the analysis of DNA copy number data, much as
recent pan-cancer and integrated genomic approaches have uncov-
ered novel cancer subtypes and driver genes (Gatza et al, 2014;
Hoadley et al, 2014). The broken chromosome synteny between
human and mouse genomes reduced the size of potential driver
regions by fivefold on average, and identified a relatively small
number of amplification and deletion regions highly conserved
between mouse and human (Figs 2D and 4E). These conserved
regions are consistently found across the majority of tumor types
examined, have subchromosomal scale with a median size on the
order of 10 megabase pairs, and include the glycolysis pathway
enzyme CNAs observed in our experimental work.
Therapeutic and diagnostic implications
The most copy number aberrant tumors tend to have fewer point
mutations in canonical oncogenes (e.g., KRAS, Fig EV2A and C) and
less canonical oncogene amplification (e.g., MYC, Fig 1B). Hence,
genomic instability and subsequent coordinate alterations in multi-
ple genes within a functional pathway may provide an alternate,
more complex, pathway to acquisition of aggressive tumor pheno-
types—with tumor evolution and selection guiding the trajectory
(Ciriello et al, 2013). In that KRAS mutation and MYC amplification
can drive glycolysis (Ying et al, 2012; Dang, 2013), the findings that
signature A tumors are de-enriched in these events relative to signa-
ture B tumors and enriched for glycolysis gene loci CNA amplifi-
cations support that tumor cells can meet their metabolic demands
through distinct mechanisms, or combinations thereof. Future
models of the most aggressive cases of cancer will need to incorpo-
rate aspects of spontaneous genomic instability (mediated by
distinct instability mechanisms) and resulting copy number alter-
ations. Translationally, understanding how CNA patterns alter
cancer genomes and impact cancer phenotypes will aid in the identi-
fication of metabolic or other “hard-wired” vulnerabilities that can
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be therapeutically targeted. Furthermore, the relative stability of
DNA samples, combined with the growing linkage between highly
recurrent copy number changes and phenotypes, supports the
potential for molecular classification and diagnostic tests based on
DNA copy number patterns (Hieronymus et al, 2014; Cai et al,
2016).
Materials and Methods
Cell culture and mouse strains
Tissue culture
CD1 mouse embryonic fibroblasts, E14.5, were purchased from
Stem Cell Technologies. p53fl/fl MEFs were obtained at day E14.5
from p53fl/fl (FVB.129P2-Trp53tm1Brn/Nci) crossed with C57BL/6-
129/SV mice. MEF cells were maintained in Dulbecco’s modified
Eagle’s medium without pyruvate and supplemented with 10% FBS
and 1% SPF. Cells were lifted and re-plated at a density of
9 × 105 viable cells/60-mm dish every 3–4 days (i.e., 3T9 protocol;
Todaro & Green, 1963). Cells were grown in atmospheric oxygen
unless otherwise indicated. Breast cancer cell lines were obtained
from the laboratory of Frank McCormick and extensively profiled
both genomically and transcriptionally by the laboratory of Joe Gray
(Neve et al, 2006; Hong et al, 2016).
Genetic engineering
Overexpression of HK1, HK2, kinase-dead HK2 (D209A/D657A), or
ENO2 glycolysis enzymes and the MYC oncogene or the control
protein RFP in CD1 MEFs was accomplished by transduction of non-
immortalized cells with pDS-FB-neo retrovirus, followed by selec-
tion in 600 lg/ml G418. Deletion of p53 in p53fl/fl MEFs was
induced by infection of non-immortalized cells with either retroviral
Cre-GFP or Cre-ERT2 plus treatment with 1 lM 4-OHT.
ROS protection
To protect cells from reactive oxygen species (ROS), cells were
cultured either at physiological oxygen concentrations (3% O2),
with 250 U/ml catalase from bovine liver (Sigma-Aldrich), or with
both 3% O2 and catalase.
Genome profiling
Array CGH profiling
Genomic DNA was harvested using the DNeasy kit (Qiagen). DNA
from MEF lines and reference genomic DNA from C57BL/6J mouse
tissue were hybridized to Agilent SurePrint G3 Mouse CGH
4 × 180 k CGH microarray chips at the UCLA Pathology Clinical
Microarray Core. Bioconductor analysis tools were used for data
processing: Moving minimum background correction and print-tip
loess normalization were performed in snapCGH package (Smith
et al, 2009); circular binary segmentation (with a minimum of three
markers per segment) was performed on smoothed and log2-
transformed copy number profiles using DNAcopy package (Seshan
& Olshen, 2016); segmented data were converted into a matrix by
genes for downstream analyses using mus musculus 9 RefSeq refer-
ence genome from 2011.08.11 in CNTools (Zhang, 2016). Copy
number profiles are presented using the Integrative Genomics
Viewer (IGV) (Thorvaldsdo´ttir et al, 2013). CNA public datasets and
TCGA tumor type abbreviations are available in the Data availability
section.
Bioinformatic and statistical analysis
PCA
Principal component analysis (PCA) was performed using the mean-
centered matrix of CNA values per gene locus. Genes with identical
profiles across samples were collapsed to a single representative
gene. Techniques such as PCA and the related singular value
decomposition (SVD) have been applied to copy number data previ-
ously (Sankaranarayanan et al, 2015).
Mutation and tumor subtype enrichment analysis
To test for enrichment of mutations or tumor subtypes within CNA-
defined PC scores, TCGA tumors were queried for mutations and
tumor subtype designations using the cBioPortal for Cancer Geno-
mics (Gao et al, 2013). For each tumor type, we included all genes
with significant q-values as calculated by MutSigCV (Lawrence et al,
2013). We also included the gene POLE, a catalytic subunit of DNA
polymerase epsilon, in our analysis because of its frequent mutation
in UCEC (The Cancer Genome Atlas Research Network, 2013).
Molecular subtypes tested were as follows: BRCA: basal, luminal,
claudin-low, and HER2-enriched (The Cancer Genome Atlas
Research Network, 2012b); LUAD: bronchioid, magnoid, and squa-
moid (The Cancer Genome Atlas Research Network, 2014); LUSC:
basal, classical, primitive, and secretory (The Cancer Genome Atlas
Research Network, 2012a); OV: proliferative, immunoreactive, dif-
ferentiated, and mesenchymal (The Cancer Genome Atlas Research
Network, 2011); and UCEC: POLE ultramutated, microsatellite insta-
bility hypermutated, copy number low, and copy number high (The
Cancer Genome Atlas Research Network, 2013). Tumors were
sorted by their PC1 score, and we calculated a Kolmogorov–Smirnov
statistic against the expected distribution of mutations or tumor
subtypes. The statistical significance of enrichment was determined
by permutation analysis.
Hierarchical clustering
The TCGA tumors were hierarchically clustered using the pheatmap
package in R (Kolde, 2015). Prior to clustering, the CNA values were
filtered for gene loci that had zero values across all tumor samples.
Non-centered and non-scaled tumor samples were then clustered
using centered Pearson correlation distance and Ward’s method
(with dissimilarities squared before cluster updating). The strength
of concordance between hierarchical clustering results and PCA-
based signatures was assessed using the hypergeometric P-value.
Consistency signatures
Consistency signatures of conserved amplification and deletions
regions were determined using stringent consistency criteria. The
signed absolute minimum consistency score (SAMCS) was defined
as non-zero when all CNA summary signatures have the same sign
across all tumor types, and the score is derived from the absolute
value-based minimum summary metric and then re-signed positive
for amplification or negative for deletion. Consistent amplifications
or deletions were combined into a “consistent region”, when abso-
lute SAMCS values greater than 0.05 spanned at least 1 Mbp. Any
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two consistent regions separated by < 1 Mbp were combined into a
single consistent region.
Enrichment analysis and weighted gene voting (WGV)
Metabolic pathway enrichment analysis (gene set enrichment analy-
sis, GSEA; Subramanian et al, 2005) and pathway-specific weighted
gene voting (WGV) prediction analysis (Golub et al, 1999) were
performed using 75 metabolic pathways defined by the Kyoto Ency-
clopedia of Genes and Genomes (KEGG) database (Kanehisa et al,
2014), using pathways with seven or more measured genes. In the
RNA-based enrichment analysis, we included a gene set consisting
of genes from the glycolysis and pentose phosphate pathways that
were upregulated in FDG-high BRCA tumors, as defined by our
previous work (Palaskas et al, 2011). For CNA data, an expanded
run of enrichment analysis was performed using 1,321 canonical
pathways (CP) of seven or more measured genes as defined by the
Broad Institute’s Molecular Signatures Database (MSigDB). For
KEGG-based metabolic pathway enrichment analysis of CNA data,
we collapsed metabolic isoenzyme loci (genes with the same
enzyme activity; Enzyme Commission [EC] numbers) that were
within 100 kilobases from each other into a single representative
locus. For mRNA expression analysis, metabolic isoenzymes were
not collapsed. In CNA-based enrichment analysis using gene-based
versions of the genome consistency signatures defined above,
enrichment scores were calculated through the ranked set of consis-
tently amplified genes since after this point the genes that are not
consistent across signatures have a consistency value of zero and
accordingly have tied ranks. Consistency regions were stepwise
restricted by sequentially adding human, and corresponding tissue-
matched mouse model of cancer, signatures based on their decreas-
ing tissue type PC1 value from Fig 1A. To combine BRCA and LU
into one enrichment analysis for mRNA data, genes were ordered by
their average rank in BRCA and LU tumor types. For WGV predic-
tions of metabolic phenotypes, t-scores were used as gene weights.
To calculate permutation P-values, we calculated the fraction of
1,000 randomly chosen gene sets of equal size that gave average
gene set rankings (column 2 of Fig 3C) better than the true gene set.
False discovery rate (FDR) q-values were calculated using the
Benjamini–Hochberg procedure. To increase statistical stringency,
FDR values for each individual glycolysis–gluconeogenesis gene set
(KEGG Glycolysis-Gluconeogenesis, KEGG Core Glycolysis, KEGG
Glycolysis-Gluconeogenesis & Pentose Phosphate Pathway, Reac-
tome Gluconeogenesis, Reactome Glucose Metabolism, Reactome
Glycolysis, Biocarta Glycolysis Pathway) were calculated while
removing the other glycolysis–gluconeogenesis gene sets. CNA and
metabolite changes were visualized in the context of metabolic path-
way structure using Cytoscape (Smoot et al, 2011).
Core glycolysis and glycolysis-associated gene list (from Fig 1F)
HK—hexokinase (HK1, HK2, HK3, HK4/glucokinase/GCK); GPI—
glucose-6-phosphate isomerase; G6PC—glucose-6-phosphatase cata-
lytic subunit (G6PC, G6PC2); FBP—fructose-bisphosphatase (FBP1,
FBP2); PFK—phosphofructokinase (PFKL—liver type, PFKM—
muscle, PFKP—platelet); PFKFB—6-phosphofructo-2-kinase/fruc-
tose-2,6-biphosphatase (PFKFB1, PFKFB2, PFKFB3, PFKFB4);
TIGAR—TP53 induced glycolysis regulatory phosphatase; ALDO—
aldolase, fructose-bisphosphate (ALDOA, ALDOB, ALDOC); TPI1—
triosephosphate isomerase 1; GAPDH—glyceraldehyde-3-phosphate
dehydrogenase (GAPDH, GAPDHS—spermatogenic); PGK—phos-
phoglycerate kinase (PGK1, PGK2); PGAM—phosphoglycerate
mutase (PGAM1, PGAM2, PGAM4, BPGM—bisphosphoglycerate
mutase); ENO—enolase (ENO1, ENO2, ENO3); PK—pyruvate kinase
(PKLR—liver and red blood cell, PKM2—muscle); LDH—lactate
dehydrogenase (LDHA, LDHB, LDHC, LDHAL6A—LDH A-like 6A,
LDHAL6B—LDH A-like 6B); and PDH—pyruvate dehydrogenase
(PDHA1, PDHA2, PDHB, DLD—dihydrolipoamide dehydrogenase,
DLAT—dihydrolipoamide S-acetyltransferase).
Metrics
Signal-to-noise ratio (SNR) = (l1  l2)/(r1 + r2), t-score =
(l1  l2)/sqrt(r12/n1 + r22/n2), where l = mean, r = standard
deviation, n = number of samples.
Correlation of mRNA and CNA
Copy number alteration and mRNA expression levels for genes found
in the cross-species conserved regions in Fig 4E were compared by
calculating the Spearman rank correlation coefficient. BRCA, LU, and
OV samples with paired mRNA and CNA data were included. UCEC
tumors were excluded because there were not sufficient UCEC
samples with paired RNA expression data (26% of all samples with
CNA data). Known oncogenes were identified by comparison with
the Catalogue Of Somatic Mutations In Cancer database (COSMIC,
http://cancer.sanger.ac.uk/cosmic; Forbes et al, 2015).
Senescence score
A summary senescence score for each MEF subline was calculated
by subtracting the area under the MEF’s growth curve, Z(x), in log2
scale, from the area under an ideal growth curve, Y(x) (i.e., consis-
tent growth at the fastest observed rate). The area difference was
then averaged by dividing by the passage number, p, and log2-trans-
formed, resulting in a normally distributed score.
Senescence Score ¼ log2
Pp
x¼2
YðxÞþYðx1Þð Þ
2 
ZðxÞþZðx1Þð Þ
2
 
p
Integrated CNA
A genomic instability score termed “integrated CNA” was calculated
by summation of the Circular Binary Segmentation algorithm-
inferred absolute mean copy number of segments multiplied by the
length of each segment.
Int.CNAsample ¼P
segments jsegment end segment startj  jsegment meanj
#base pairs in sample
Box and whisker plots
In box and whisker plots, the box represents the median, as well as
the first and third quartiles, and the whisker indicates the extreme
values within 1.5 times the inter-quartile range. In cases where the
number of samples permitted, individual values are superimposed
as jitter plots.
Statistical tests
Indicated P-values were calculated using (i) Student’s t-test for
normally distributed data (with normality confirmed by the P-value
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of the Shapiro–Wilk test being > 0.05 for both datasets under
comparison); (ii) Mann–Whitney U-test for non-normally distributed
data; (iii) hypergeometric distribution P-values; and (iv) permuta-
tion-based approaches, as described in the figure legends. For data
with a single data point in one comparison group, the z-score was
used.
Propidium iodide staining
Mouse embryonic fibroblasts cells were washed in cold PBS and
then fixed in ice-cold 70% ethanol. Fixed cells were washed in PBS
and then incubated for 15 min in PBS with 20 lg/ml propidium
iodide and 0.1% (v/v) Triton X-100. Data were acquired using a
FACSCalibur (Becton Dickinson) analytic flow cytometer in the
UCLA Jonsson Comprehensive Cancer Center and Center for AIDS
Research Flow Cytometry Core Facility. Cells were gated using
forward scatter and side scatter to remove debris and dead cells,
and 10,000 cell events were recorded.
Spectral karyotyping
Exponentially growing MEF cells were exposed to colcemid
(0.04 lg/ml) for 1 h at 37°C and to hypotonic treatment (0.075 M
KCl) for 20 min at room temperature. Cells were fixed in a mixture
of methanol and acetic acid (3:1 by volume) for 15 min, and then
washed three times in the fixative. Slides were prepared by dropping
the cell suspension onto wet slides followed by air-drying. Slides
were processed for spectral karyotyping (SKY) according to the
manufacturer’s protocol with slight modifications using mouse paint
probes (ASI, Vista, CA). Images were captured using Nikon 80i
microscope equipped with spectral karyotyping software from ASI,
Vista, CA; 12–18 metaphases were karyotyped from each cell line.
Immunoblot analysis
Cells were lysed in modified RIPA buffer (50 mM Tris–HCl (pH 7.5),
150 NaCl, 10 mM b-glycerophosphate, 1% NP-40, 0.25% sodium
deoxycholate, 10 mM sodium pyrophosphate, 30 mM sodium fluo-
ride, 1 mM EDTA, 1 mM vanadate, 20 lg/ml aprotinin, 20 lg/ml
leupeptin, and 1 mM phenylmethylsulfonyl fluoride). Whole-cell
lysates were resolved by SDS–PAGE on 4–15% gradient gels and
blotted onto nitrocellulose membranes (Bio-Rad). Membranes were
blocked overnight and then incubated sequentially with primary
and either HRP-conjugated (Pierce) or IRDye-conjugated secondary
antibodies (Li-Cor). Blots were imaged using the Odyssey Infrared
Imaging System (Li-Cor). Protein levels were quantitated using
ImageJ (http://imagej.nih.gov/ij/). Primary antibodies used for
Western blot analysis included hexokinase 1 (2024, Cell Signaling
Technology), hexokinase 2 (2867, Cell Signaling Technology), p53
(NB200-103, Novus Biologicals), and enolase 2 (8171, Cell Signaling
Technology).
Glucose consumption and lactate secretion measurements
BRCA cell lines
Lactate secretion rates of breast cancer cell lines were measured
from the culture media using a colorimetric assay kit (BioVision)
(Hong et al, 2016).
MEFs
Glucose consumption and lactate secretion rates of MEFs were
measured using a BioProfile Basic bioanalyzer (NOVA Biomedical).
Data were normalized to the integrated cell number, which was
calculated based on cell counts at the start and end of the time
course and an exponential growth equation. Because the prolifera-
tion rates of MEF sublines vary, each cell line was seeded at the
appropriate density so as to give an integrated cell number of
approximately 6.5 × 105 cells in a 6-well plate. All samples were
run as biological triplicates, and consistent results were seen in
multiple independent experiments.
Mass spectrometry-based metabolomic analyses
Sample preparation
Mouse embryonic fibroblasts sublines were seeded onto 6-well
plates, and after 24 h, media was replaced with media containing
4.5 g/l [1,2-13C]-labeled glucose. Sample collection occurred after
24 h of culture in the labeled glucose media. For intracellular
metabolite analysis, cells were washed with ice-cold 150 mM
ammonium acetate (NH4AcO) pH 7.3 and metabolites extracted in
1 ml ice-cold 80% MeOH. The cells were quickly transferred into a
microfuge tube, and 10 nmol norvaline was added to the cell
suspension for use as an internal standard. The suspension was
subsequently vortexed three times over 15 min and then spun down
at 4°C for 5 min. The supernatant was transferred into a glass vial,
the cell pellet was re-extracted with 200 ll ice-cold 80% MeOH and
spun down and the supernatants were combined. Metabolites were
dried at 30°C under vacuum and re-suspended in 50 ll of 70%
acetonitrile (ACN). For cell culture media metabolite analysis (foot-
print profiling), 20 ll of cell-free media samples was collected.
Metabolites were extracted by adding 300 ll ice-cold 80%
methanol, followed by vortexing three times over 15 min, and
centrifugation for 10 min at 13,000 rpm at 4°C. The supernatant
was transferred to a fresh tube, dried using a vacuum evaporator,
and re-suspended in 50 ll of 70% acetonitrile (ACN); 5 ll was used
for mass spectrometry-based analysis.
Mass spectrometry runs
Samples were run on a Q-Exactive mass spectrometer coupled to an
UltiMate 3000RSLC UHPLC system (Thermo Scientific). The mass
spectrometer was run in polarity switching mode (+3.00 kV/
2.25 kV) with an m/z window ranging from 65 to 975. Mobile
phase A was 5 mM NH4AcO, pH 9.9, and mobile phase B was ACN.
Metabolites were separated on a Luna 3 lm NH2 100 A˚
(150 × 2.0 mm) (Phenomenex) column. The flow was kept at
200 ll/min, and the gradient was from 15% A to 95% A in 18 min,
followed by an isocratic step for 9 min and re-equilibration for
7 min.
Data analysis
Metabolites were detected and quantified as area under the curve
(AUC) based on retention time and accurate mass (≤ 3 ppm) using
the TraceFinder 3.1 (Thermo Scientific) software. Relative amounts
of metabolites between various conditions, percentage of metabolite
isotopomers (relative to all isotopomers of that metabolite), and
percentage of labeled metabolite molecules (isotopomer M1 and
greater, relative to all isotopomers) were calculated and corrected
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for naturally occurring 13C abundance (Yuan et al, 2008). Footprint-
ing data were normalized to the integrated cell number as described
above, and intracellular metabolite concentrations were normalized
to the number of cells present at the time of extraction. All samples
were run as biological triplicates, and consistent results were seen
in independent experiments. Our analysis focused on metabolite
level, percent isotopomer, and percent labeled metabolite measure-
ments with ANOVA P-values across the sample panel of < 0.05 in
individual experiments, and Pearson correlation coefficients across
all samples and between independent experiments of > 0.5.
Patient tumor samples and quantitative FDG-PET imaging
Breast cancer patient samples with imaged FDG uptake within
4 weeks prior to surgery, excluding patients with secondary breast
cancers and recurrent disease, were collected surgically and
processed as previously described (Palaskas et al, 2011). Of eigh-
teen tumors collected in the original study for RNA microarrays
(Palaskas et al, 2011), ten samples had sufficient remaining frozen
tissue for array CGH profiling. None of the patients received
systemic therapy or radiation prior to imaging. 18FDG tumor uptake
was quantified as standardized uptake values (SUVs) and showed
the expected wide dynamic range (3.8–18.5). There was no signifi-
cant difference in patient age, tumor volume, and lymph node
involvement between the groups of FDG-high and FDG-low breast
cancers. Breast cancers with high 18FDG-PET SUVs frequently
lacked expression of the estrogen receptor (ER) and the proges-
terone receptor (PR), but hormone receptor-negative tumors were
also represented among the tumors with the lowest FDG uptake
(Palaskas et al, 2011). We excluded lobular breast carcinomas,
because they have been shown to take up less FDG than ductal
carcinomas (Avril et al, 2001) We excluded large breast carcinomas
(> 5 cm) and breast carcinomas with multifocal FDG uptake
because our protocol did not include tissue autoradiography to
direct the molecular tissue analysis to areas of distinct radiotracer
retention. This study was approved by the Institutional Review
Board (IRB) of Memorial Sloan-Kettering Cancer Center, and all
participating patients signed the informed consent.
Data availability
CNA dataset
Copy number profiling data for wild-type and genetically modified
MEF samples and FDG-PET-imaged human breast tumors are
available through Gene Expression Omnibus (GEO) accession
GSE63306 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=
GSE63306).
CNA conservation web resource
An interactive website for user-defined pan-cancer and cross-species
CNA conservation analysis to perform analysis analogous to that in
Figs 1C, 2D, and 4E using any combination of tens of available CNA
signatures from human tumors and mouse models (and additional
signatures as they become available) and/or the inclusion of
uploaded CNA signatures (http://systems.crump.ucla.edu/cna_con
servation/). Signatures and genome reference files used in the inter-
active website are additionally available through the Biostudies
repository, accession number S-BSST7.
Metabolomics dataset
Provided in Table EV5.
TCGA CNA dataset
The Cancer Genome Atlas (TCGA) CNA profiles were downloaded
from the TCGA portal in September 2012 (https://cancergenome.
nih.gov/). Copy number profiles obtained were pre-processed level
3 data based on human genome 19, with copy number variations
(CNVs) removed. TCGA tumor type abbreviations and number of
samples analyzed: bladder urothelial carcinoma (BLCA, 97
samples), brain lower grade glioma (LGG, 181), breast invasive
carcinoma (BRCA, 873), colon adenocarcinoma (COAD, 447),
glioblastoma multiforme (GBM, 593), head and neck squamous cell
carcinoma (HNSC, 308), kidney renal clear cell carcinoma (KIRC,
539), lung adenocarcinoma (LUAD, 368), lung squamous cell carci-
noma (LUSC, 359), ovarian serous cystadenocarcinoma (OV, 584),
prostate adenocarcinoma (PRAD, 171), rectum adenocarcinoma
(READ, 168), skin cutaneous melanoma (SKCM, 256), stomach
adenocarcinoma (STAD, 162), thyroid carcinoma (THCA, 333), and
uterine corpus endometrial carcinoma (UCEC, 492).
TCGA mRNA expression dataset
The Cancer Genome Atlas mRNA expression data were downloaded
from the TCGA portal in May 2014. Gene-based mRNA expression
levels were pre-processed, normalized Level 3 RNA Seq V2 RSEM
values. TCGA tumor type abbreviations and number of samples
analyzed: BRCA (865), LUAD (357), LUSC (358), OV (263).
Mouse tumor model CNA datasets
The genetically engineered mouse models with characterized CNA
were obtained from public datasets: mammary (breast) tumors
(Brca, 57 samples, GSE30710; 62 samples, GSE43997; 44 samples,
GSE27101) (Drost et al, 2011; Herschkowitz et al, 2012); melanoma
(Skcm, 30 samples, GSE58265) (Viros et al, 2014); glioblastoma/
high-grade astrocytoma (Gbm, 72 samples, GSE22927) (Chow et al,
2011); and prostate tumors (Prad, 18 samples GSE35247; 55
samples, GSE61382) (Ding et al, 2012; Wanjala et al, 2015). Addi-
tionally, in vitro epithelial murine cell lines modeling human carci-
nomas were obtained from public datasets: transformed colon cells
(Coad, seven samples, GSE70790) and transformed bladder and
kidney cells (Blca and Kirc, 6 and 7 samples, GSE45128; Padilla-
Nash et al, 2013). Abbreviated mouse tumor names match to the
corresponding tissue-based human tumor abbreviations from the
TCGA datasets. The data were obtained from GEO and segmented
using the algorithm described above. Datasets for which no mm9
genome annotation was available on the repository were lifted over
to mm9 using UCSC web tools (Rosenbloom et al, 2015).
Expanded View for this article is available online.
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